Vernalis PLC Rule 2.9 Announcement (6206R)

TIDMVER

RNS Number : 6206R

Vernalis PLC

15 June 2018

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

15 June 2018

Vernalis plc ("Vernalis", the "Company", or the "Group")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, Vernalis confirms that as at the date of this announcement, it has 526,986,000 ordinary shares of one pence each in issue and admitted to trading on the AIM market of the London Stock Exchange. There are no shares held in treasury. Accordingly, the total number of voting rights in Vernalis is 526,986,000. The International Securities Identification Number ("ISIN") for the Company's ordinary shares is GB00B3Y5L754.

Vernalis has a Sponsored Level 1 American Depositary Receipt ("ADR") facility in the United States with ISIN US92431M2061, with each ADR representing two Vernalis ordinary shares of one pence each in the issued share capital of the Company. The Company's ADRs are traded on the US over-the-counter market under the symbol 'VNLPY'.

Enquiries:

 
 Vernalis plc:                                 [phone] 
 Ian Garland, Chief Executive Officer 
  David Mackney, Chief Financial Officer 
 Canaccord plc (Nominated Adviser and Joint 
  Broker):                                     [phone] 
 Henry Fitzgerald-O'Connor 
  Emma Gabriel 
 FTI Consulting (Financial Communications):    [phone] 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
 Evercore (Financial Adviser):                 [phone] 
 Julian Oakley 
  Alan Beirne 
 

Notes to Editors

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

For further information about Vernalis, please visit www.vernalis.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RTTSFLFMIFASESM

(END) Dow Jones Newswires

June 15, 2018 12:07 ET (16:07 GMT)